Literature DB >> 23981009

Patient, physician, and procedural factors influencing the use of defibrillation testing during initial implantable cardioverter defibrillator insertion: findings from the NCDR®.

Andrea M Russo1, Yongfei Wang, Sana M Al-Khatib, Jeptha P Curtis, Rachel Lampert.   

Abstract

BACKGROUND: Advances in implantable cardioverter defibrillator (ICD) technology have resulted in more effective defibrillation, and the need for defibrillation threshold (DFT) testing has been questioned.
METHODS: A total of 64,227 initial ICD implant procedures performed at 1,261 facilities (April to December 2010) in the NCDR Registry™ were selected to identify patterns of practice related to DFT testing. Patient, physician, and procedural characteristics were compared. Independent association of DFT testing with in-hospital adverse events or mortality was also examined.
RESULTS: DFT testing was performed in 71% of patients. Patients who did not undergo testing were older; more often had heart failure, lower left ventricular ejection fraction, atrial arrhythmias, and a primary prevention indication; and were more likely to receive a cardiac resynchronization therapy device. In addition, patients who did not undergo testing were less likely to be implanted in a metropolitan area and more often implanted at a teaching hospital, in New England, in the Mid-Atlantic, or in the Pacific U.S . In-hospital adverse events occurred in 2.56% of patients who underwent DFT testing compared to 3.58% who did not (P < 0.001). Death or any complication remained more likely to occur in patients who did not undergo testing (odds ratio and 95% confidence interval: 1.46 [1.33, 1.61], P < 0.001), after adjusting for baseline and procedural differences.
CONCLUSIONS: DFT testing is not performed in many (29%) patients in clinical practice. Patients who did not undergo testing were more likely to have adverse events and to be older with more comorbidities, which could explain why DFT testing was avoided. Prospective randomized data are needed to determine the impact of DFT testing on outcome. ©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  arrhythmia; defibrillation testing; implantable cardioverter defibrillator; registry

Mesh:

Year:  2013        PMID: 23981009     DOI: 10.1111/pace.12248

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  7 in total

1.  [Annual report 2013 of the German Cardiac Pacemaker And Defibrillator Register--Part 2: implantable cardioverter-defibrillators. Pacemaker and AQUA Institute for Applied Quality Improvement and Research in Health Care GmbH workgroup].

Authors:  A Markewitz
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-12

2.  [Annual Report 2012 of the German Heart pacemaker defibrillator round register: Section on pacemaker and AQUA Institute for Applied Quality Improvement and Research in Health Care GmbH].

Authors:  A Markewitz
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-12

3.  Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry.

Authors:  Daniel J Friedman; Craig S Parzynski; E Kevin Heist; Andrea M Russo; Joseph G Akar; James V Freeman; Jeptha P Curtis; Sana M Al-Khatib
Journal:  Circulation       Date:  2018-02-20       Impact factor: 29.690

4.  Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life.

Authors:  Faisal M Merchant; Paul Jones; Scott Wehrenberg; Michael S Lloyd; Leslie A Saxon
Journal:  J Am Heart Assoc       Date:  2014-11-10       Impact factor: 5.501

5.  2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.

Authors:  Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesœs Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang
Journal:  J Arrhythm       Date:  2016-02-01

6.  Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator.

Authors:  Mohammad-Ali Jazayeri; Martin P Emert; JoAnn Bartos; Ted Tabbert; Dhanunjaya R Lakkireddy; Mohammad-Reza Jazayeri
Journal:  HeartRhythm Case Rep       Date:  2017-05-25

7.  Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice.

Authors:  Ryan T Borne; Tiffany Randolph; Yongfei Wang; Jeptha P Curtis; Pamela N Peterson; Frederick A Masoudi; Amneet Sandhu; Matthew M Zipse; Kevin Thomas; Valentina Kutyifa; Nihar R Desai; Yong-Mei Cha; Jonathan C Hsu; Andrea M Russo
Journal:  JAMA Netw Open       Date:  2019-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.